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Abstract
Background: Oxidative stress induced by smoking is considered to be important in the pathogenesis of Chronic
Obstructive Pulmonary Disease (COPD). Heme oxygenase-1 (HMOX1) is an essential enzyme in heme catabolism
that is induced by oxidative stress and may play a protective role as an antioxidant in the lung. We determined
whether HMOX1 polymorphisms were associated with lung function in COPD patients and whether the variants
had functional effects.
Methods: We genotyped five single nucleotide polymorphisms (SNPs) in the HMOX1 gene in Caucasians who had
the fastest (n = 278) and the slowest (n = 304) decline of FEV1 % predicted, selected from smokers in the NHLBI
Lung Health Study. These SNPs were also studied in Caucasians with the lowest (n = 535) or the highest (n = 533)
baseline lung function. Reporter genes were constructed containing three HMOX1 promoter polymorphisms and
the effect of these polymorphisms on H2O2 and hemin-stimulated gene expression was determined. The effect of
the HMOX1 rs2071749 SNP on gene expression in alveolar macrophages was investigated.
Results: We found a nominal association (p = 0.015) between one intronic HMOX1 SNP (rs2071749) and lung
function decline but this did not survive correction for multiple comparisons. This SNP was in perfect linkage
disequilibrium with rs3761439, located in the promoter of HMOX1. We tested rs3761439 and two other putatively
functional polymorphisms (rs2071746 and the (GT)n polymorphism) in reporter gene assays but no significant
effects on gene expression were found. There was also no effect of rs2071749 on HMOX1 gene expression in
alveolar macrophages.
Conclusions: We found no association of the five HMOX1 tag SNPs with lung function decline and no evidence
that the three promoter polymorphisms affected the regulation of the HMOX1 gene.
Keywords: Heme oxygenase, polymorphism, chronic obstructive pulmonary disease
Background
Oxidative stress induced by smoking is considered to
play a role in the pathogenesis of Chronic Obstructive
Pulmonary Disease (COPD). Oxidant compounds in
cigarette smoke cause an excess of oxidants in the lung,
and lead to direct cell injury, lung extracellular matrix
damage, inactivation of antiproteinases, and induction of
proinflammatory mediators [1].
Heme oxygenase-1 (HMOX1) is an essential enzyme
in heme catabolism and is induced by oxidative stress.
HMOX1 catalyzes the conversion of heme to biliverdin,
carbon monoxide and iron. Subsequent to the reaction,
biliverdin is converted to bilirubin by biliverdin reduc-
tase. Biliverdin and bilirubin have been shown to act as
scavengers of reactive oxygen species, and carbon mon-
oxide has also been shown to possess anti-inflammatory
effects (reviewed in [2]). In both in vitro and in vivo stu-
dies, murine cells lacking Hmox1 have been reported to
be susceptible to oxidative injury [3], and exogenous
delivery of Hmox1 by gene transfer in the rat lung was
shown to provide protection against hyperoxia-induced
injury [4]. The results of these studies suggest that
HMOX1 has a protective role as an antioxidant in the
lung.
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impact of smoking by modulating the severity of the
smoke-induced injury and thus the severity of chronic
airflow obstruction [5]. Antioxidant genes have been
considered to be plausible candidate genes for this sus-
ceptibility [6]. In this study, we investigated whether
variations of the HMOX1 gene were associated with the
level of lung function in smokers who had mild to mod-
erate airway obstruction. To identify potential causal
variants in the HMOX1 gene, we analyzed a set of highly
informative single nucleotide polymorphism (SNP) mar-
kers which covered the gene including the promoter
region.
Methods
Genetic association analysis in the Lung Health Study
Study participants
The National Heart, Lung, and Blood Institute Lung
Health Study (LHS) is a multicenter clinical study with
5,887 participants who had spirometric evidence of
mild-moderate lung function impairment [6,7]. The lung
function values for each participant were compared to
the predicted normal values of Crapo et al. [8]. Lung
function impairment was defined by a forced expiratory
volume in one second (FEV1) to forced vital capacity
(FVC) ratio of ≥ 0.70 and FEV1 55%-90% of predicted.
Participants of European descent were selected from the
cohort, and two nested case control studies were
designed based on the rate of lung function decline and
the lung function at the start of the LHS. First, indivi-
duals who had the most and least rapid rate of decline
of lung function were selected from those who contin-
ued to smoke for the duration of the 5 years follow up.
Those whose FEV1% predicted decreased by ≥ 3.0%/year
during the 5 year period (fast decline group, n = 278)
were compared with those whose FEV1%p r e d i c t e d
increased ≥ 0.4%/year (non-decline group, n = 304). Sec-
ond, subjects who had the highest post-bronchodilator
FEV1%p r e d i c t e d( ≥ 88.9%; high function group, n =
533) and subjects who had lowest post-bronchodilator
FEV1% predicted (≤ 67.0%; low function group, n = 535)
at the start of the LHS were compared. Since 139 sub-
jects included in the fast or non-decline groups had
baseline lung function within these criteria, they were
also included in the baseline function study. Informed
consent was obtained from each individual, and the pre-
sent study protocol was approved by the Providence
Health Care Research Ethics Board.
TagSNP selection and genotyping
Information from the SeattleSNPs website http://pga.gs.
washington.edu was used for the selection of the
HMOX1 SNPs. There were 28 SNPs whose minor allele
frequency was more than 10% in the HMOX1 gene
sequence (GenBank accession# AY460337). Pairwise
linkage disequilibrium (LD) statistics for the SNPs
were visualized by the Haploview 4.1 software [9] and
are shown in Figure 1. TagSNPs were chosen from
these SNPs using the ldSelect program (version 1.0)
[ 1 0 ] .A nL Dt h r e s h o l do fr
2 >0 . 8w a ss e ti nt h ep r o -
gram. Assays to genotype rs17882950, rs17880288,
rs2018488 and rs1807714 could not be established and
therefore these SNPs were excluded from the study. In
total, five SNPs were genotyped using TaqMan assays
(Applied Biosystems, Carlsbad, CA). These SNPs
tagged 86% (24/28) of the SNPs present in this region
i nt h eP G AE u r o p e a np a n e l .T h eo n l yc o d i n gS N P
among these tags was rs2071747 that resulted in a
change of amino acid from aspartate to histidine at
position 7 of the polypeptide. As expected there was
no strong LD between the five tag SNPs although
rs2071746 showed moderate LD with rs9610289 and
rs2071749 (r
2 = 0.60 and 0.65, respectively). The LD
between all other pairs of SNPs was r
2 < 0.40.
Detection of potential transcription factor binding sites in
the promoter sequence
The online software tool, MatInspector [11] was used to
identify consensus sequences for transcription factor
binding sites. This tool is available at http://www.geno-
matix.de.
Transient-Transfection Assay
Construction of reporter gene vectors
rs2071746 and the GT repeat polymorphism, which
have been reported as functional variants in previous
studies [12,13], are located between rs3761439 and the
transcription start site. We conducted reporter gene
assays to elucidate the possible effect of these 3 poly-
morphisms on the promoter activity. Since rs3761439
was in complete LD (D’ = 1) with rs2071746, we
excluded the rs3761439A - rs2071746T haplotype which
was expected not to exist in our subjects. We selected
2 3 ,3 0 ,a n d3 7G Tr e p e a t sa sr e p r e s e n t a t i v ea l l e l e so f
small (S) (< 27 repeats), medium (M) (27 - 32 repeats),
and large (L) (≥ 33 repeats) classes, respectively because
these were the most common alleles of those classes in
our study population.
A 1.3 kb fragment containing nucleotides -1,301 to
+22 from the transcription start site of the HMOX1
gene, including the rs3761439 and rs2071746 SNPs and
the (GT)n repeat polymorphism, was amplified by poly-
merase chain reaction (PCR) using the forward primer
5’-ATT CGC TAG CCA TCC CAG GCT CAA GTG
AAC-3’ and the reverse primer 5’-CTG AGG ACG CTC
GAG AGG A-3’.P C Rw a sp e r f o r m e du s i n gPfuUltra
High-Fidelity DNA Polymerase (Stratagene, La Jolla,
CA) as described by the manufacturers. The PCR pro-
ducts were then digested with NheIa n dXhoI, and each
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mega, Madison, WI) between these restriction sites.
Site-specific mutation for rs2071746 was performed to
make plasmids 2, 4, and 8 (see Figure 2) following the
protocol of the QuikChange II site-directed mutagenesis
k i t( S t r a t a g e n e ,L aJ o l l a ,C A ) .P r i m e r sf o rt h em u t a g e n -
esis reactions were: 5’-GCC CAC CAG GCT ATT GCT
CTG AGC AGC G-3’ and 5’-CGC TGC TCA GAG
CAA TAG CCT GGT GGG C-3’ for plasmids 2 and 8;
5’-GCC CAC CAG GCT TTT GCT CTG AGC AGC G-
3’ and 5’-CGC TGC TCA GAG CAA AAG CCT GGT
GGG C-3’ for plasmid 4.
To construct plasmids 3 and 9, sequences that had 23
and 37 GT repeats were digested with PstIa n dXhoI,
and each fragment was cloned into plasmid 6 (which
originally had 30 GT repeats between these restriction
sites).
The sequence fidelity of each construct was confirmed
by DNA sequencing. Quantification of plasmid DNA
concentration was performed using Quant-iT PicoGreen
dsDNA reagent and kits (Invitrogen, Carlsbad, CA).
Transfection and luciferase assay
A549 cells (American Type Culture Collection number
CRL-1848) were cultured in Dulbecco’s modified Eagle
medium supplemented with 10% fetal bovine serum. For
luciferase assay 5 × 10
4 cells were plated on 24-well
plates, and were cultured overnight. The plasmids were
transfected into A549 cells using Fugene 6 nonliposomal
reagent, according to the manufacturer’sp r o t o c o l
(Roche Diagnostics, Lewes, UK). After 24 h, the cells
were treated with medium with or without stimuli for
another 18 h. H2O2 (300 μM) and hemin (100 μM)
were used as stimuli. Hemin was dissolved in medium
with 0.5% DMSO, and the control for the hemin was
treated with the same medium without hemin. The cells
were then harvested and assayed following the Dual-
Luciferase reporter assay system protocol (Promega,
Madison, WI). Luciferase activity was corrected for
transfection efficiency using a co-transfected renilla-luci-
ferase vector with the experimental plasmid at a ratio of
1:10. Three or four independent experiments were car-
ried out, and each assay was performed in triplicate.
HMOX1 expression in alveolar macrophages
Samples
Genomic DNA and total RNA were isolated from alveo-
lar macrophages of 58 individuals who underwent lung
resection for a small (< 3 cm), Stage I or II, peripheral
tumor at Vancouver General Hospital between July 2001
and November 2004, as described previously [14]. This
study was approved by the University of British Colum-
bia/Providence Health Care and Vancouver Hospital
Figure 1 Single-nucleotide polymorphisms (SNPs) in the region of the heme oxygenase 1 (HMOX1) gene whose allele frequency was >
10% in European-American Coriell samples. Shading represents the strength of pair-wise linkage disequilibrium (LD) with a black-to-white
gradient reflecting higher to lower r
2 values. Bin: a group of SNPs where the alleles are highly associated. *: tag SNPs; †: SNPs which were
excluded from the study.
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jects provided written informed consent.
The resected lung or lobe was obtained immediately
post-operatively and bronchoalveolar lavage was per-
formed. Details of the lavage, macrophage separation
and subsequent culture are as described previously [14].
For each sample, we assessed the following conditions:
fresh alveolar macrophages, non-stimulated macro-
phages after 24 hours of culture, and LPS-stimulated
macrophages after 24 hours of culture.
Genotyping
Genomic DNA from the alveolar macrophages was gen-
otyped for the rs2071749 SNP by TaqMan assay
(Applied Biosystems).
Quantitative PCR
cDNA samples were prepared from alveolar macro-
phages and were used to determine the gene expression
of HMOX1. The reference gene used was GNB2L1,a
guanine nucleotide-binding protein as this was pre-
viously shown to be stably expressed in alveolar macro-
phages [15]. Gene expression assays for HMOX1
(Hs00157965_m1) and GNB2L1 (Hs00272002_m1) were
from Applied Biosystems.
Statistical Analysis
We examined whether genotype frequencies were com-
patible with Hardy-Weinberg equilibrium using the
genetics package for R http://www.r-project.org.
Fisher’s exact test was performed for the 3-by-2 tables
of the codominant model using R. Multivariate logistic
regression was used to adjust for age, sex, pack-years
of smoking, and the recruiting research center. Haplo-
type frequencies were estimated with an EM algorithm
using the R haplo.stats package. Haplotype association
was performed using hapassoc [16], a contributed R
package.
For the transient transfection assay data, the Kruskal-
Wallis test was used to compare fold increase of lucifer-
ase activity by H2O2 or hemin. For testing the 9 plas-
mids, the p value was confirmed by examining the
distribution of Kruskal-Wallis statistics using randomly-
generated data through computer simulation (10,000
permutations). For assessment of statistical significance
of each SNP in the assay, the Wilcoxon rank-sum test
was used. A p value < 0.05 was considered significant.
For the analysis of gene expression in alveolar macro-
phages, a relative expression ratio was calculated from
the real-time PCR efficiencies and the cycle threshold
(CT) values for the samples, as described previously [17].
All three genotypes (GG n = 14; AG n = 32; AA n =
12) were examined to compare relative expression of
HMOX1.T h eJMP 5.1 statistical software package (SAS
Institute Inc., Cary, NC, USA) was used for assessment
of statistical significance of HMOX1 expression among
the three genotypes. A p value < 0.05 was considered
significant.
luc
1G  - T  - 2 3
2G  - A  - 2 3
3A  - A  - 2 3
4G  - T  - 3 0
5G  - A  - 3 0
6A  - A  - 3 0
7G  - T  - 3 7
8G  - A  - 3 7
9A  - A  - 3 7
Basal promoter activity Fold increase Fold increase
11 2 3 1 2 3
H2O2 Hemin
Plasmid 
Figure 2 HMOX1 gene promoter analysis of 9 different constructs. Each test construct was co-transfected into A549 cells with Renilla
luciferase vector as an internal control. The basal promoter activity of each plasmid is indicated as luciferase activity relative to that of construct
1. The relative inducibility by H2O2 (300 μM) or Hemin (100 μM) is shown for each construct. Data are presented as means + SD from three to
four independent experiments. There was no significant difference in induction of reporter gene expression among these constructs.
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Characteristics of the LHS study participants
The characteristics of the LHS participants are shown in
Table 1. Several potentially confounding factors were
significantly different between the fast and non decline
groups and between the low and high baseline groups,
as reported previously [18].
Single SNP analysis in the LHS
We analyzed each of the selected SNPs in the rate of
lung function decline sub-study and the baseline lung
f u n c t i o ns u b - s t u d y( T a b l e2 ) .Am u l t i v a r i a t el o g i s t i c
regression model was used to adjust for confounding
factors including age, gender, pack-years of smoking,
and research center in the analyses. All the SNPs were
in Hardy-Weinberg equilibrium. We found a nominally
significant difference in genotype frequencies of
rs2071749 between the fast and non decline groups
(Table 2). However, this association was not significant
after correction for multiple comparison (p = 0.075). In
addition, the rs2071749 SNP was not associated with
rate of decline of lung function expressed as a continu-
ous variable (change in FEV1% predicted) in the fast
decline group (p = 0.41).
The LD in the LHS dataset between the SNPs and the
GT repeat polymorphism previously reported to be
associated with emphysema [13] is shown in Table 3.
The repeat polymorphism was stratified into two
“alleles” based on repeat length i.e. the L allele as pre-
viously described [13] vs. all other alleles. In this analy-
sis, only the rs2071747 SNP was in high LD with the
repeat polymorphism (Table 3).
Haplotype analysis in the LHS
We analyzed the distribution of haplotypes of the five
HMOX1 SNPs (Table 4). As in the single SNP analyses,
we adjusted for potential risk and confounding factors.
There was no significant association between the
HMOX1 haplotypes and lung function in the two
studies.
Promoter sequence analysis
The tagSNP, rs2071749, which is located in intron 3 in
the HMOX1 gene, was in perfect LD (r
2 =1 )w i t h
rs3761439, which is in the promoter region. We ana-
lyzed the promoter region using tools which detect con-
sensus sequences for transcription factor binding sites.
We found that rs3761439 changed the consensus
sequence of an NF-B binding site [GGG(A/G)NN(T/C)
(T/C)CC]. The matrix similarity of the rs3761439G
sequence (Ggggtctccc) for NF-B was 0.888, which was
higher than the optimized matrix similarity thresholds,
Table 1 Characteristics of participants in the rate of lung function decline sub-study and the baseline lung function
sub-study










Female/Male 115/163 101/203 0.04 205/330 180/353 0.12
Age (years) 49.5 ± 6.7 47.6 ± 7.0 0.0005 50.7 ± 6.9 46.2 ± 6.9 < 0.0001
Smoking (pack-years) 43.0 ± 18.3 38.3 ± 17.4 0.003 45.3 ± 18.5 35.4 ± 18.5 < 0.0001
ΔFEV1, % predicted/yr* -3.44 ± 1.17 0.68 ± 1.05 < 0.0001 -0.78 ± 1.85 -0.75 ± 1.39 0.73
Baseline FEV1, % predicted† 74.8 ± 8.3 80.0 ± 8.7 < 0.0001 62.6 ± 2.3 91.8 ± 2.3 < 0.0001
Data are presented as means ± SD. Lung function was measured after administration of bronchodilator.
* Change in lung function per year over a 5 year period
† Lung function at the start of the Lung Health Study
Table 2 Single nucleotide polymorphisms (SNPs) in the HMOX1 region genotyped in this study
MAF in the rate of decline study MAF in the baseline study
SNP Alleles
(major/minor)
Fast decline Non decline P value* Low function High function P value*
rs9610289 G/A 0.301 0.311 0.689 0.342 0.342 0.894
rs2071746 A/T 0.405 0.434 0.223 0.429 0.436 0.931
rs2071747 G/C 0.058 0.065 0.163 0.050 0.046 0.656
rs2071749 G/A 0.495 0.452 0.015 0.475 0.458 0.184
rs2285112 A/G 0.356 0.370 0.572 0.397 0.395 0.933
MAF = minor allele frequency
* P values in the table are for the codominant model and are adjusted by multivariate logistic regression for age, sex, pack-years of smoking, and research center.
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lower than 0.60, which was the lowest threshold of the
software.
Transient transfection assay
The results of the transient transfection assay are shown
in Figure 2. There were no significant differences in the
promoter activity between the constructs under basal
conditions. We found a significant increase of luciferase
activity following stimulation by H2O2 and hemin, how-
ever, we did not detect any significant difference in the
relative inducibility among the constructs (p = 0.91 for
H2O2 stimulation, p = 0.42 for hemin stimulation).
There was also no significant difference in the inducibil-
ity in single locus assessment of each polymorphism e.g.
for rs3761439 comparing plasmids 2, 5, and 8 (allele G)
vs. plasmids 3, 6 and 9 (allele A).
HMOX1 expression in alveolar macrophages
The genotype distribution of the rs2071749 SNP fulfilled
the Hardy Weinberg equilibrium (GG (0.25), AG (0.56),
AA (0.21); p = 0.71).
In the fresh alveolar macrophages, the AG genotype of
rs2071749 was associated with 1.28 fold higher HMOX1
gene expression while the AA genotype was associated
w i t ha1 . 0 6f o l dh i g h e rg e n ee x p r e s s i o ni nc o m p a r i s o n
to the GG reference group, but these differences were
not significant. In the non-stimulated alveolar
macrophages after 24 hours in culture, the AG and AA
genotypes were associated with higher HMOX1 expres-
sion by 1.10 and 1.24 fold, respectively, when compared
to the GG genotype but these differences were not sig-
nificant. Similarly, in the LPS-stimulated alveolar macro-
phages both the AG and AA genotypes showed higher
expression of 1.19 and 1.12 fold, respectively, with
respect to the GG reference group. However, these dif-
ferences were not significant. There was also no signifi-
cant difference in the change in gene expression i.e.
comparing LPS-stimulated HMOX1 expression minus
non-stimulated expression.
Discussion
We found a borderline significant association between
one tagSNP, rs2071749, and lung function decline in
smokers who had mild to moderate airway obstruction.
This intronic tagSNP was in perfect LD (r
2 =1 )w i t h
rs3761439, which is located in the promoter region of
the HMOX1 gene. We tested rs3761439 and two other
putatively functional polymorphisms (rs2071746 and the
(GT)n polymorphism) in reporter gene assays but no
effects on gene expression were found.
The (GT)n polymorphism in the HMOX1 gene was
investigated in a Japanese study population [13] and the
L class of alleles (≥ 33 repeats) was significantly asso-
ciated with pulmonary emphysema in smokers [13]. The
(GT)n polymorphism was also associated with level of
lung function in early-onset COPD families and with
COPD [19] but not with measures of functional impair-
ment [20]. In the LHS, no association was found
between (GT)n repeat classes and the rate of decline of
lung function [6]. In contrast, Guenegou et al. reported
an association between lung function decline and the
(GT)n polymorphism in the European Community
Respiratory Health Survey (ECRHS) [21]. Similar results
were reported in Japanese [22] and Dutch populations
[23].
Lung function traits were investigated in both the
ECRHS [21] and the LHS [6]. However, the criteria for
recruitment of subjects and the methods of analysis
Table 3 Linkage disequilibria between the HMOX1 single
nucleotide polymorphisms (SNPs) and the GT repeat
polymorphism previously reported to be associated with
emphysema [13]
SNP Linkage disequilibrium statistic
D’ r
2 P value
rs9610289 0.916 0.0285 < 0.001
rs2071746 0.932 0.0920 < 0.001
rs2071747 0.985 0.8309 < 0.001
rs2071749 0.891 0.0547 < 0.001
rs2285112 0.839 0.0308 < 0.001
Table 4 Haplotype analysis of the HMOX1 gene
Rate of decline study Baseline study
Haplotype
† Fast decline Non decline P value* Low function High function P value*
ATGGG 0.299 0.309 0.71 0.326 0.342 0.47
GAGAA 0.492 0.450 0.474 0.455
GAGGA 0.095 0.111 0.084 0.100
GTCGA 0.057 0.064 0.048 0.048
GTGGG 0.046 0.056 0.051 0.042
Haplotype frequencies were estimated with an EM algorithm implemented in haplo.stats.
† Haplotypes formed from polymorphisms in the following order: rs9610289, rs2071746, rs2071747, rs2071749, rs2285112.
* P values are adjusted by multivariate logistic regression for age, sex, pack-years of smoking, and research center. P values are derived from a global test of the
difference in distribution of the five haplotypes between the two phenotypic groups.
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study of the LHS we used a nested case control design
that allowed comparison of phenotypic extremes within
a cohort of smokers selected for evidence of mild/mod-
erate airflow obstruction. Therefore, disease severity
genes were investigated in the LHS, while disease sus-
ceptibility genes were investigated in the ECRHS. This
may be the basis of the discrepant results between the
two studies [6,21]. Alternatively, our study may be a
false negative result due to lower sample size. The pre-
vious studies that demonstrated an association of the
(GT)n polymorphism and lung function decline had
sample sizes of 749 [21], 101 [22], and 1390 [23] and
therefore a larger sample size than that used in our
study may be required to show the effect of this repeat
polymorphism.
The tagSNP that was nominally associated with lung
function decline in this study (rs2071749) was in perfect
LD (r
2 = 1) with a SNP that was located in the promoter
region of the HMOX1 gene (rs3761439). The promoter
SNP was predicted to change the sequence of an NF-B
b i n d i n gs i t ea n dt h e r e f o r em a yb et h ec a u s a lS N Pf o r
the association. We hypothesized that the G allele of
rs3761439 was associated with relative resistance to lung
function decline in smokers because it caused higher
expression of the HMOX1 gene in response to specific
stimuli.
Therefore, we conducted a functional analysis of the
HMOX1 promoter. Two polymorphisms, rs2071746
(designated A-413T by Ono et al. [12]) and the (GT)n
polymorphism, both of which were reported as func-
tional [12,13], are located between rs3761439 and the
transcriptional start site of the gene. Previously Yamada
et al. showed in A549 cells that H2O2 exposure up-regu-
lated the transcriptional activity of the HMOX1 promo-
ter with S alleles of (GT)n but not with M or L alleles
[13]. In lymphoblastoid cell lines, HMOX1 mRNA
expression, HMOX1 activity, and resistance to oxidant-
induced apoptosis were significantly higher in cells with
the S/S genotypes than those with L/L [24]. However, it
is still unknown whether the higher activities of
HMOX1 were due to the (GT)n polymorphism, because
the polymorphisms in this region are in strong LD with
each other. Indeed, Ono et al. demonstrated that the A
allele of rs2071746, but not the S allele of (GT)n,w a s
associated with higher basal promoter activity in a
reporter gene assay using bovine aortic endothelial cells
[12].
To elucidate the functional consequences of promoter
polymorphisms on HMOX1 inducibility by oxidative
stress, we made nine plasmid constructs for reporter
gene assays, based on the haplotype structure of the
(GT)n, rs2071746, and rs3761439 polymorphisms. We
used A549 cells and stimulated them with H2O2 or
hemin. Hemin is known as an inducer of HMOX1, and
generates reactive oxygen species. However, we did not
detect any significant difference of the promoter activity
among the nine plasmids in the transient transfection
assays, in contrast to the previous in vitro functional
studies [12,13,24]. Our negative results in the transient
transfection assays may be related to regulatory
sequences that were not included in the plasmids in this
study but were included in the constructs utilized in the
previous studies. We did not include a pGL3-basic vec-
tor in the experimental design as we were interested in
the fold increase in gene expression i.e. comparing
before and after H2O2 and hemin stimulation. This deci-
sion was motivated by the previous study by Yamada et
al. [13] that demonstrated that the up-regulation of a
reporter gene in response to H2O2 differed between pro-
moters of different haplotypes. Nevertheless, this is a
limitation of our study design.
Conclusions
We found that none of the five tag SNPs in the HMOX1
region was related to lung function decline in smokers.
This supports our previous results in the LHS where we
investigated the (GT)n polymorphism. In addition, we
did not demonstrate that the three investigated HMOX1
polymorphisms had an effect on the promoter activity
of the gene in transient transfection assays and the
rs2071749 SNP was not associated with HMOX1 in
alveolar macrophages. These results suggest that the
causal variant(s) that underlie the previous associations
with COPD remain to be determined.
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